论文部分内容阅读
目的观察多西紫杉醇联合卡培他滨治疗蒽环类耐药的转移性乳腺癌的临床疗效及不良反应。方法 28例既往接受过蒽环类、(其中7例接受过紫杉醇)等药物化疗的转移性乳腺癌患者,均有临床观察指标,采用多西紫杉醇联合卡培他滨化疗2～4个周期,观察近期疗效。结果 28例患者中,3例CR,16例PR,7例SD,2例PD,总有效率(CR+PR)67.8%。主要不良反应为骨髓抑制及手足综合征。结论多西紫杉醇联合卡培他滨治疗蒽环类耐药的转移性乳腺癌疗效确切,不良反应轻,耐受性好,值得临床推广。
Objective To observe the clinical efficacy and adverse reactions of docetaxel plus capecitabine in the treatment of anthracycline-resistant metastatic breast cancer. Methods Twenty-eight patients with metastatic breast cancer, who had previously received anthracycline chemotherapy (7 of them received paclitaxel) and other drugs, had clinical observation. Docetaxel combined with capecitabine chemotherapy for 2 to 4 cycles, Observe the short-term effect. Results Of the 28 patients, 3 were CR, 16 were PR, 7 were SD, and 2 were PD. The total effective rate (CR + PR) was 67.8%. The main adverse reactions were myelosuppression and hand-foot syndrome. Conclusion Docetaxel combined with capecitabine in the treatment of anthracycline-resistant metastatic breast cancer has definite curative effect, mild adverse reactions and good tolerability, which is worthy of clinical promotion.